Despite accumulating evidence pointing to a genetic basis for tardive dyskinesia, results to date have been inconsistent owing to limited statistical power and limitations in molecular genetic methodology. A Medline, EMBASE and PsychINFO search for literature published between 1976 and June 2007 was performed, yielding 20 studies from which data were extracted for calculation of pooled estimates using meta-analytic techniques. Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT val158met , using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR = 0.63, 95% CI: 0.46-0.86, P = 0.004) and Met carriers (OR = 0.66, 95% CI: 0.49-0.88, P = 0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR = 1.30, 95% CI: 1.03-1.65, P = 0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR = 1.80, 95% CI: 1.03-3.15, P = 0.037); (3) in MnSOD Ala9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR = 0.37, 95% CI: 0.17-0.79, P = 0.009) and for Val carriers (OR = 0.49, 95% CI: 0.24-1.00, P = 0.047). These analyses suggest multiple genetic influences on TD, indicative of pharmacogenetic interactions. Although associations are small, the effects underlying them may be subject to interactions with other loci that, when identified, may have acceptable predictive power. Future genetic research will take advantage of new genomic knowledge.
Introduction
Since the introduction of antipsychotic medication in 1952, tardive dyskinesia (TD), characterized by hyperkinetic involuntary movements of the choreoathetoid type with a fluctuating intensity over time, 1, 2 is still a major concern as a potentially irreversible side effect, which can be distressing for patients owing to motor performance difficulties, social stigmatization and poorer quality of life. 3 Studies on genetic factors related to TD are often inconsistent owing to genetic methodological problems, such as sample heterogeneity, small effects of multiple genes, (epi)genetic interactions, pleiotropy and small sample size. 4 Meta-analyses may usefully increase the power to produce a more precise estimate, provided studies are comparable and methodologically sound. 5, 6 In this article, a meta-analysis of the genes that are thought to be associated with TD, namely COMT, DRD2, CYP1A2 and MnSOD, is presented. Genetic variation in DRD3 in relation to TD was already meta-analysed recently and therefore it is not included in this study. 7 
Methods
Choice of candidate genes Attractive candidate genes for TD are (1) genes related to schizophrenia and dysregulation of the dopamine system because part of the risk for TD is thought to be associated with schizophrenia, 8 (2) genes related to the metabolism of antipsychotics because these drugs are at least partly responsible for TD [9] [10] [11] [12] and (3) genes related to free radicals because several theories concerning TD are related to damage of the dopamine receptor.
Catechol-O-methyltransferase. The catechol-O-methyltransferase gene (COMT), which encodes a central dopamine catabolic enzyme that co-regulates dopamine levels in the brain, contains an single nucleotide polymorphism (SNP) located in exon 4, a G-A substitution at codon 158 changing valine (Val) to methionine (Met), causing a missense mutation resulting in a lower metabolic activity and lower stability form Met of the COMT enzyme. [15] [16] [17] A haplotype combining COMT val158met (rs4680) with two common SNPs located in intron 1 (rs737865) and in the 3 0 flanking region (rs165599) was highly associated with schizophrenia, 18 and differentially affected expression of rs4680 alleles in human brain tissue. 19 These findings have led to the hypothesis that COMT val158met may not directly result in disease, but may be in strong linkage disequilibrium (LD) with the etiological, not yet identified, variant. 20 In addition, this three-marker haplotype is significantly heterogeneous across populations worldwide, despite relatively equal prevalence of schizophrenia. An SNP in the 5 0 flanking region (rs2097603) in the P2 promoter, which is responsible for the transcription of the predominant form of COMT in the brain, is in LD with rs737865 and varies across populations, and may play an important role in schizophrenia. 21, 22 Given the fact that part of the risk for TD is thought to be associated with dopaminergic function, polymorphisms in COMT are attractive candidates for the study of TD. It has been hypothesized that patients with the Met variant have a higher risk for TD, as a result of either post-synaptic dopamine receptor supersensitivity or elevated levels of free radicals owing to an increased level of dopamine in the brain. 23 Dopamine 2 receptor Dopamine 2 receptor (DRD2) is of particular interest because of its high density in areas thought to be implicated in schizophrenia. 24 In addition, DRD2 is densely expressed in the basal ganglia. [25] [26] [27] Taq1A. The DRD2 Taq1A polymorphism resides in the overlapping ANKK1 gene, a kinase gene which is involved in signal transduction. 28 Taq1A1 carrier status (A1A1 and A1A2 genotypes) was associated with a lower D2 receptor density in the striatum and related structures of the human brain in vitro 29, 30 and in vivo. [31] [32] [33] The study by Laruelle 31 showed an opposite trend in patients with schizophrenia compared to controls, which may be confounded by prior antipsychotics use in the former group. This was confirmed by another study, which did find a higher D2 receptor density in patients with schizophrenia after intake of antipsychotics. [34] [35] [36] DRD2 Ser311Cys and À141C Ins/Del. The Ser311Cys polymorphism is an effective cAMP inhibitor in DRD2 leading to activation of intracellular signalling. 27, 37 The À141C Del allele of the À141C Ins/Del polymorphism was associated with a decrease of DRD2 promoter activity in vitro 38 and an increase of striatal D2 binding in vivo, 33 although this latter finding was not confirmed in another study.
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CYP1A2
Cytochrome P450 1A2 (CYP1A2), a member of the cytochrome P450 mixed-function oxidase system, metabolizes atypical antipsychotics, including clozapine and olanzapine. Although it has low-affinity for typical antipsychotics compared to the high affinity CYP2D6, this enzyme is much more abundant in the liver (high capacity) and is induced by smoking, making it an important enzyme during saturation during the long-term treatment with typical agents. 12 Prevalence rates of exonic SNPs of the CYP1A2 gene are too rare for association studies. On the other hand, regulatory and intronic regions contain several SNPs giving rise to more than 30 allelic variants, of which, however, only very few have been functionally characterized.
A putative polymorphism in intron 1 of CYP1A2 (À163C > A; CYP1A2*1F allele) appears to affect the inducibility of CYP1A2. 40 Thus, the CYP1A2*1F A/A genotype may represent a CYP1A2 with high inducibility, which may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. CYP1A2*1F thus was associated with a 40% lower activity in smokers carrying the CC compared to the AA genotype, but not in nonsmokers. 41 Patients with the CC genotype had 2.7-and 3.4-fold higher AIMS-scores compared to the A/C and A/A genotype, respectively. Among smokers, the AIMS-scores were 4.7-and 5.4-fold higher, respectively. 42 This result was not replicated in later studies in TD patients. [43] [44] [45] The CYP1A2*1C allele (À3860G > A) also results in a lower activity in smokers. 46 Free radicals. The neuronal degeneration hypothesis, in the context of neuronal death or neurotoxicity, has been proposed as an alternative to the 'dopamine supersensitivity hypothesis'.
14 One argument for the neuronal degeneration hypothesis is that the supersensitivity hypothesis may not fit the clinical course of TD because (1) although hypersensitivity seems to be a universal response to D2-receptor antagonists, not all patients develop TD, (2) TD tends to display an irreversible course, whereas dopamine supersensitivity diminishes gradually upon cessation of antipsychotics and (3) the risk for TD is markedly elevated with age, but the dopamine supersensitivity response may be dampened with increasing age. 13 In one study, TD symptoms correlated positively with markers of excitatory neurotransmission and protein carbonyl group and negatively with CSF superoxide dismutase (SOD), suggesting elevated levels of oxidative stress are relevant to the pathophysiology of TD.
14 Thus, as toxic effects of free radicals may contribute to the development of TD, genetic variants of free radical scavenging enzymes like manganese superoxide dismutase (MnSOD) have been investigated, which is localized in the mitochondria. The gene encoding MnSOD has one polymorphic site, resulting in an alanine (Ala) to valine (Val) substitution causing less efficient transport of MnSOD in the mitochondrion in rat liver cells and HuH7 human hepatoma cells. [47] [48] [49] [50] [51] Literature search A systematic literature review of the literature published between 1976 and June 2007 was conducted with the help of Medline, EMBASE and PsychINFO using key words: (genetic) polymorphism(s), tardive dyskinesia, extrapyramidal (syndrome/disorder), drug-induced, antipsychotic(s), adverse effect/event, catechol-Omethyltransferase gene (COMT), dopamine D2 receptor (DRD2), cytochrome P 450 1A2 (CYP1A2) and manganese superoxide dismutase (MnSOD). In addition, all relevant references cited in these articles were also retrieved.
Inclusion and exclusion criteria
Only those studies were included that examine associations with antipsychotic-induced TD and the polymorphisms of COMT, DRD2, CYP1A2 and MnSOD.
Statistics
Analyses were conducted using the METAN routine of the STATA statistical program (StataCorp (2007): STATA Statistical Software: Release 9.0. Texas: College Station), version 9.2, providing pooled estimates, confidence limits and a test that the true pooled effect is zero, obtained from fixed and random-effects meta-analysis. A test for heterogeneity between studies and an estimator of between-studies variance is provided. Pooled odds ratios (ORs) were calculated by providing, for each study, the number of individuals in each of the four cells made up by the combination of a binary exposure (the genetic polymorphism) and a binary outcome (TD or not). Comparisons were conducted comparing both genotypes (with a1a1 genotype as reference category) and allelotypes (with a1 allelotype as reference category). Allele frequencies given genotypic frequencies of a1a1, a2a1 and a2a2 were calculated as follows: frequency a1 = 2*(a1a1) þ (a1a2); frequency a2 = 2*(a2a2) þ (a1a2).
For studies reporting on non-overlapping samples within one study, for example, because of stratification for duration of illness, samples were entered separately into the meta-analysis. Standard corrections of 0.5 to all cells in 2 Â 2 tables were adopted in case of one or more zero cells to avoid computational difficulties.
Meta-analytic results were assessed for heterogeneity in effect sizes between studies, and Egger's test for publication bias was carried out using the STATA METABIAS routine, yielding a regression coefficient (B) representing the bias estimate. Both fixed and random-effects methods were used with results being inspected for discrepancies, as recommended by the Cochrane Collaboration (http://www.cochrane-net. org/openlearning/HTML/mod13-4.htm).
Results
Catechol-O-methyltransferase
Studies included. Three studies reported inconclusive results on the association between COMT val158met and TD. [52] [53] [54] Matsumoto et al. 54 only carried out the allelic analysis. Han et al. 55 included only male Korean patients and found a significant association between COMT val158met genotypes and alleles on the one hand and TD on the other with protective effect for the Met allele, Val-Met and Met-Met genotype compared to the Val and Val-Val reference groups, but not for EPS. Srivastava et al. 56 studied four SNPs of COMT and TD, and found a significant genotypic association for COMT val158met with a protective effect for the Met-Met genotype, as well as significant allelic and genotypic association for genotype GG with 408 C > G (exon 4) with increased risk for the G allele, CG and GG genotype compared to the C and CC reference groups. Associated haplotypes also yielded significant results. However, results were not significant following linear and logistic regression analyses.
The search yielded five studies for the alleles and four for the genotypes as Matsumoto 54 did not include genotypes. All groups (with and without TD) were in Hardy-Weinberg equilibrium (HWE), except for the TD group in the study of Lai et al. 53 The study of Srivastava et al. 56 did not provide information on HWE. A meta-analysis of the five samples, yielding a total of 382 patients with TD and 707 without, was conducted.
52-56
Heterogeneity and bias. Meta-analytic results. In the allelic analyses, using the Val variant as reference category, the fixed-effects model pooled OR for the Met variant was directionally protective at 0.84, albeit not statistically significant at conventional a (95% CI: 0.69-1.02, P = 0.075), with a similar result for the random-effects model (OR = 0.82, 95% CI: 0.58-1.16, P = 0.260).
In the genotypic analyses, using Val-Val homozygotes as reference category, the pooled OR was 0. 
Dopamine 2 receptor
Studies included. Early studies did not show an association with Taq1A or other polymorphisms. [56] [57] [58] [59] [60] [61] One study found a significant association between the Taq1A polymorphism of the dopamine 2 receptor gene (DRD2) and TD in female patients. 62 Another study showed an increased risk for EPS in patients with the À141C Del allele of the DRD2 gene. 63 A recent study investigated 12 polymorphisms in the DRD2 gene in relation to TD in European Caucasian (n = 202) and African-American (n = 30) patients, and found significant associations for the genotype frequencies for C957T and the adjacent C939T polymorphisms. Two-marker haplotypes containing C939T and C957T were significantly associated with both TD and total AIMS scores. C957T may be associated with TD in the AfricanAmerican sample.
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Taq1A. The search yielded 11 studies. Six studies could not be included because either categorical data were not used 61 or data were not reported, 56, 59, 60, 64 or Chinese language was used in the article. 65 As both Chen et al. 62 and Liou et al. 66 recruited patients in the same location in Taipei, Taiwan, only the latter study was included to avoid the risk of overlap.
All groups (with and without TD) were in HWE. Liou et al. 66 did not provide information on HWE. As Zai et al. 27 studied both alleles and genotypes in relation to TD in Caucasians, but only alleles in Afro-Americans, we included the Caucasian population in the meta-analysis.
A meta-analysis of the four samples, yielding a total of 297 patients with TD and 467 without, was conducted. Meta-analytic results. In the allelic analyses, using the A1 variant as reference category, the fixed-effects model pooled OR for the A2 variant was 1.30 (95% CI: 1.03-1.65, P = 0.026; Figure 3 ), which concurred with the random-effects model (OR = 1.30, 95% CI: 1.03-1.65, P = 0.027).
Using A1-A1 homozygotes as reference category, the pooled OR was 1.80 (95% CI: 1.03-3.15, P = 0.037; Figure 4 ) for A2-A2 homozygotes, 1.15 (95% CI: 0.70-1.90, P = 0.579) for the A1-A2 heterozygotes and 1.33 (95% CI: 0.83-2.14, P = 0.229) for the A2 carriers using the fixed-effects model. In the random effects model, the ORs were 1.77 (95% CI: 0.97-3.21, P = 0.062) for A2-A2 homozygotes, 1.15 (95% CI: 0.69-1.89, P = 0.599) for the A1-A2 heterozygotes and 1.32 (95% CI: 0.82-2.13, P = 0.249) for the A2 carriers.
Ser311Cys and À141C Ins/Del. For both polymorphisms, the search yielded nine studies. Five studies could not be included either because categorical data were not used 61, 69 or data were not reported. 56, 59, 60 No large or significant pooled OR was found for the alleles or genotypes for Ser311Cys 58, [66] [67] [68] or for À141C Ins/Del 27,66-68 (results available upon request). There was no evidence of heterogeneity or publication bias, although there was some indication for publication bias for the Ser311Cys allele comparisons (B = 3.56, 95% CI: À0.25 to 7.37, P = 0.057).
CYP1A2
CYP1A2*1F.
Studies included One study on CYP1A2*1F showed a significant association with TD for the C-alleles and C-containing genotypes, 44 but this result The search for CYP1A2*1F yielded seven studies. One study could not be included because categorical data were not used. 42 In the analyses, no significant pooled OR was evident for allelic or genotypic comparisons of this polymorphism. 12, [43] [44] [45] 70, 71 To improve the signal-to-noise ratio, a metaanalysis was done of available data in the subgroup of smokers, 43, 45, 70 which did not result in a large or significant effect. The fixed-effects model pooled OR for the alleles was 1.06 (95% CI: 0.73-1.53, P = 0.771), and 1.06 (95% CI: 0.73-1.53, P = 0.768) using the random-effects model. Using A-A homozygotes as reference category, the pooled OR was 1.41 (95% CI: 0.58-3.42, P = 0.450) for C-C homozygotes, 0.90 (95% CI: 0.54-1.51, P = 0.702) for the A-C heterozygotes and 0.97 (95% CI: 0.59-1.59, P = 0.902) for the C carriers using the fixed-effects model, and 1.41 (95% CI: 0.58-3.45, P = 0.449) for C-C homozygotes, 0.90 (95% CI: 0.54-1.52, P = 0.703) for the A-C heterozygotes and 0.97 (95% CI: 0.59-1.59, P = 0.902) for the C carriers using the random effects model. There was no evidence of heterogeneity or publication bias.
In Asians and even more pronounced in Asian smokers, CYP1A2 may play a more important role in antipsychotic metabolism, because Asians display lower mean CYP2D6 activity compared to Caucasians owing to high prevalence of the CYP2D6*10 allele (56.2% of Chinese and 38.8% of Japanese). 72 The pooled OR of all Asians 12, [43] [44] [45] and available data in the subgroup of smokers 43, 45 did not result in a large or significant OR. There was no evidence of heterogeneity or publication bias.
In the subgroup of Asian smokers, both the fixedeffects and random-effects model pooled OR for the alleles were 1.16 (95% CI: 0.75-1.81, P = 0.503). Using A-A homozygotes as reference category, the pooled OR was 1.45 (95% CI: 0.53-3.94, P = 0.472) for C-C homozygotes, 1.09 (95% CI: 0.58-2.05, P = 0.797) for the A-C heterozygotes and 1.15 (95% CI: 0.63-2.11, P = 0.650) for the C carriers using the fixed-effects model, and 1.45 (95% CI: 0.53-3.99, P = 0.471) for C-C homozygotes, 1.09 (95% CI: 0.58-2.05, P = 0.797) for the A-C heterozygotes and 1.15 (95% CI: 0.63-2.11, P = 0.649) for the C carriers using the random effects model.
CYP1A2*1C.
Studies included Two studies with CYP1A2*1C 12, 45 showed no significant pooled OR for contrasting alleles or genotypes (results available upon request). With only two studies, publication bias could not be assessed.
MnSOD. Studies included
One study showed a significant association between a biallelic polymorphism and TD 73 and one study did not. 74 A pooled analysis of these two Asian samples performed by Pae 75 resulted in inconclusive results. However, when Pae added an Eastern Turkish sample 76 to the previous two Asian samples, the pooled analysis gave strong significant results. This effect was explained by the higher prevalence of À9Ala in Europeans compared to Asians, as well as methodological differences. It has been suggested to include other polymorphisms of MnSOD in the analyses. 75 Hitzeroth et al. 47 did a study with AIMS instead of TD-scores in a Xhosa population and found a significant association in the genotypic, but not the allelic analyses. Figure 4 Meta-analysis: odds ratios (OR) and 95% confidence intervals (CI) for tardive dyskinesia (TD) in Taq1A in DRD2, using A1-A1 as reference category, a risk increasing effect for A2-A2 homozygotes in four samples included in the pooled analysis. Pooled OR = 1.80 (95% CI: 1.03-3.15, P = 0.037) in fixed effects model.
The search yielded six studies. Two studies could not be included because Polish language was used 77 or data were not reported. 75 Hitzeroth et al. 47 provided us with TD data. All groups (with and without TD) were in HWE, except for the patients in the study by Akyol et al. 76 A meta-analysis of the four samples, yielding a total of 134 patients with TD and 546 without, was conducted. 47, 73, 74, 76 Heterogeneity and bias Significant heterogeneity was apparent for the allelic analyses (w 2 Table 1 ).
Conclusion
This study extends previous work in the pharmacogenetic field of TD as the meta-analysis offers a stronger basis for a polygenetic component for the pharmacogenetic interactions underlying TD. Evidence from pooled data for positive genetic association with TD shows significant effects for (1) COMT val158met with decreased risk for Val-Met heterozygotes and for Met carriers compared to the Val-Val reference group; (2) Taq1A in DRD2 with increased risk for the A2 allele and A2-A2 genotype compared to the A1 and A1-A1 reference groups; (3) MnSOD, with decreased risk for Ala-Val and Val carriers compared to the Ala-Ala reference group.
In contrast with the theory of a higher risk of TD in relation to the Met-variant in COMT and the Val-variant of MnSOD, the current meta-analysis shows an opposite effect. These results suggest different mechanism(s), such as less extra cellular dopamine production in patients with high activity COMT gene. 55 Alternatively, this result may be due to haplotypic heterogeneity across populations. 21 The meta-analysis of Taq1A in DRD2 resulted in convincing ORs with a higher risk in A2 for TD. On the other hand, the group of Zai et al. 27 showed opposing trend which could be explained by inclusion of a Caucasian population; the other studies included Asian or a mix of Ashknazi/non-Ashknazi patients.
We found no heterogeneity in most analyses, possibly because of a lack of power. However, visual inspection of the forest plots does not suggest a large degree of heterogeneity. Not all studies could be included due to unavailable data, but little evidence for publication bias was found. Furthermore, caution is required in generalizing the findings to entire genes, as not all polymorphisms in the genes were studied. Nonsignificant results may be due to small effect size in genetic studies, which usually need larger samples than the studies included in this metaanalysis. In addition, the inconclusive results could reflect ethnic diversity with other functional polymorphisms in LD, that is, the existence of a true pathogenic mutation close to a studied candidate gene may differ between ethnic groups. 78 In future, association studies should be replicated using withinfamily control methodology (transmission/disequilibrium test), 79 as this was not used in any of the studies of genes and TD.
Although the significant associations are small, various combinations of susceptibility genes may converge on synaptic processing in microcircuits, affecting a final common pathway of dysfunction and related symptoms, and secondary morphological alterations. 80, 81 Furthermore, findings of small effects should be placed into the proper context with respect to interactions with other genetic susceptibility loci, including additive and epistatic types. 13, 16, 24 Muller et al.
2 calculated that the overall prediction model of patients' AIMS in their study, with more than half of the variance predicted by polymorphic variation in DRD3 and CYP1A2 in addition to covariates, had a predictive power that was similar to the test for cardiac enzymes to detect myocardial infarction.
Moreover, the small effects indicate involvement of other genes in the development of TD. Previously, other genes were included in meta-analyses such as (1) the gene encoding for 5-HT2A 82 (a) showing a small but significant association of the T102C genotype in several subgroups of TD and (b) the 5-HT2A His452Tyr polymorphism that showed a significant association with TD in a two-locus haplotype with T102C, (2) the joint comparison group of deficient alleles (*3, *4, *5) with TD 10 and (3) the gene encoding for DRD3 7, 83 showed a significant excess of the Gly-allel and Gly-Gly homozygotes of the Ser9Gly polymorphism in patients with schizophrenia and TD. The meta-analysis of Bakker et al. 7 showed a reduced or even opposite tendency in Asians compared to non-Asians.
It has been suggested that with the introduction of SGAs, TD is disappearing and no longer of much clinical concern. However, SGAs still carry a risk of movement disorder. [84] [85] [86] [87] In addition, many patients continue to take FGAs in combination with SGAs. 88, 89 Furthermore, the WHO (http://www.who.int/medicines/en) advocates the use of essential medicines; these are medicines with several characteristics such as serving priority health care needs and cost-effectiveness. As the three antipsychotic drugs enlisted in the most recent (15th) World Health Organization Model List of Essential Medicines are FGA, TD remains an important research topic, especially in developing countries but also in developed countries where health care coverage is not universal.
Future genetic research into antipsychotic-induced TD will take advantage of the expanding numbers of single nucleotide polymorphisms. In addition, genome wide association studies will be possible in the near future. 90, 91 Furthermore, pharmacogenetics improved our understanding of the pathogenesis and risk factors of TD, 78 and may contribute to the development of psychopharmacotherapeutics that are applicable at the level of the individual patient. Table 1 Continued
Antipsychotic-induced TD in COMT, DRD2, CYP1A2 and MnSOD genes PR Bakker et al
